Developer · RAPP · United States

Rapport Therapeutics, Inc.

Clinical-stage biotechnology company (Nasdaq: RAPP) based in Boston and San Diego developing small molecule precision medicines for neurological and psychiatric disorders, built on a platform targeting receptor-associated proteins (RAPs) in the brain. Lead asset RAP-219, a TARPγ8-selective AMPA receptor negative allosteric modulator, is in Phase 3 for focal onset seizures and completed a positive Phase 2 in bipolar mania; RAP-641, an α6β4 nAChR agonist, is in IND-enabling work for chronic pain and migraine.

rapportrx.com ↗

1compound
2programs
2indications
Phase 3lead asset

Phase distribution

  • Phase 31
  • Phase 21

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • Mar 10, 2026Licensing dealRapport licenses Greater China rights to RAP-219 to Tenacia BiotechnologyRapport granted Tenacia Biotechnology rights to develop and commercialize RAP-219 in Greater China (mainland China, Hong Kong, Macau, Taiwan) across multiple indications including focal onset seizures and bipolar mania, for $20M upfront, about $308M in development and commercialization milestones and other payments, and tiered royalties from mid-single digits to mid-teens on Greater China net sales. Rapport retains all other territories.RAP-219source ↗

Catalysts · 2 upcoming · 2 reported

  • Q4 2026Anticipated

    RAP-219forEpilepsyInterim analysis

    Initial data from the open-label long-term safety trial of RAP-219 in focal onset seizures expected in Q4 2026.

    NCT07219407source ↗

  • July 2029Anticipated

    RAP-219forEpilepsyRegistry results

    ClinicalTrials.gov estimated primary completion of Phase 3 FOCUS-1 (RAP-219 in focal seizures): July 2029.

    NCT07563881source ↗

Recently reported

  • 2026-10-20met

    RAP-219forBipolar disorderTopline data

    Positive Phase 2 topline for RAP-219 in acute bipolar mania: 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045); CGI-BP mania severity also significant (p=0.024); well tolerated.

    source ↗

  • 2025-09-08met

    RAP-219forEpilepsyTopline data

    Positive Phase 2a topline in drug-resistant focal onset seizures: 85.2% achieved ≥30% long-episode reduction (p<0.0001); median clinical seizure reduction 77.8% (p=0.01); 24% seizure-free over 8 weeks.

    source ↗

Recent activity

  • Oct 20, 2026ReadoutRAP-219·Bipolar disordermetPositive Phase 2 topline for RAP-219 in acute bipolar mania: 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045); CGI-BP mania severity also significant (p=0.024); well tolerated.source ↗
  • Aug 5, 2026Phase changeRAP-219·Bipolar disorderPhase 2Primary completion reached (registry actual date, 253 enrolled); the trial is Active, not recruiting during post-treatment follow-up. Positive topline announced 2026-10-20.source ↗
  • Jun 5, 2026Phase changeRAP-219·EpilepsyPhase 3Pivotal Phase 3 FOCUS-1 (NCT07563881) started (registry actual start date). Rapport reported on 2026-08-05 that the Phase 3 program began in Q2 2026 with FOCUS-1 and FOCUS-2 both enrolling.source ↗
  • Sep 26, 2025Phase changeRAP-219·EpilepsyPhase 2Phase 2a FOS-201 reached primary completion (registry actual date) after positive topline results for the 8-week treatment period were announced on 2025-09-08.source ↗
  • Sep 8, 2025ReadoutRAP-219·EpilepsymetPositive Phase 2a topline in drug-resistant focal onset seizures: 85.2% achieved ≥30% long-episode reduction (p<0.0001); median clinical seizure reduction 77.8% (p=0.01); 24% seizure-free over 8 weeks.source ↗
  • Jul 25, 2025Phase changeRAP-219·Bipolar disorderPhase 2Phase 2 trial RAP-219-BPM-201 (NCT07046494) in bipolar I disorder with acute mania started (registry actual start date).source ↗
  • Oct 10, 2024Phase changeRAP-219·EpilepsyPhase 2Open-label Phase 2a proof-of-concept trial RAP-219-FOS-201 (NCT06377930) started in adults with drug-resistant focal onset seizures with an implanted RNS System (30 enrolled).source ↗

Trials recruiting · 3 recruiting of 5 sponsored

  • Phase 3RAP-219n=3122 sites · United States

    Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    Focal SeizureEpilepsyFocal EpilepsyNCT07594119 ↗

  • Phase 3RAP-219n=3333 sites · United States

    Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    Focal SeizureEpilepsyFocal EpilepsyNCT07563881 ↗

  • Phase 2RAP-219n=307 sites · United States

    A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

    Focal EpilepsyEpilepsyRefractory Focal EpilepsyNCT07219407 ↗

Competitive landscape

Other companies developing against Rapport Therapeutics, Inc.'s targets or indications.